ライフサイエンスコーパス: Taxus

1 taxane C-10 hydroxyl acetyl transferase from Taxus.

2 sels were randomly assigned 3:2 to CoStar or Taxus.

3 1,675 (98.5%) were evaluable (CoStar = 989; Taxus = 686), including 1,330 (79%) single-vessel and 34

4 10-O-acetyltransferase along with five other Taxus acyltransferases on the paclitaxel (Taxol) biosynt

5 The baseline Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score (bSS) from 2,68

6 low to intermediate Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score (random-effects

7 ween Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Score is an objective

8 ween Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score of 32 or lower

9 as assessed by the Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score.

10 ween Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial demonstrated th

11 ween Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial is a multicente

12 ween percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) trial is the most imp

13 LM patients in the Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) trial, the largest tr

14 ween Percutaneous Coronary Intervention With Taxus and Cardiac Surgery [SYNTAX]; NCT00114972).

15 (SYNergy Between PCI With TAXus and Cardiac Surgery [SYNTAX]; NCT00114972).

16 ercutaneous coronary intervention (PCI) with TAXUS and Cardiac Surgery trial, 1800 patients with 3-ve

17 tion of the SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score has prompted a renewed

18 P<0.0001), SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score of >/=11 (the sample me

19 ween Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score quantifies the extent o

20 nd the mean SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score was 19.7 +/- 9.6.

21 d diabetes, SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) score, treatment of saphenous

22 ween Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) scores and lesion characteris

23 ween percutaneous coronary intervention with TAXus and cardiac surgery) study randomly assigned 1,800

24 ween Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) trial, patients with 3-vessel

25 omes of the SYNTAX (SYNergy Between PCI With TAXUS and Cardiac Surgery) trial.

26 ween Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial.

27 similar in the 2 groups, 16.4% and 22.5% in TAXUS and control, respectively (P=0.12), including comp

28 ercutaneous coronary intervention (PCI) With Taxus and coronary artery bypass surgery (CABG)] score i

29 The TAXUS ATLAS study is a global, prospective, single-arm t

30 Using Taxus baccata, a conifer species without resin, we devel

31 her (Cordis Corp., Miami Lakes, Florida) and Taxus (Boston Scientific Corp., Natick, Massachusetts) D

32 r the Cypher (Cordis, Miami, Florida) or the Taxus (Boston Scientific, Maple Grove, Minnesota) stent

33 Johnson & Johnson, Warren, New Jersey], 17% Taxus [Boston Scientific, Maple Grove, Minnesota]).

34 akes, Florida) and paclitaxel-eluting stent (TAXUS, Boston Scientific Corp., Natick, Massachusetts) w

35 SES, n = 69), and paclitaxel-eluting stents (Taxus, Boston Scientific, Natick, Massachusetts) (PES, n

36 tent anticancer drug first isolated from the Taxus brevifolia Pacific yew tree.

37 ted with recombinant taxadiene synthase from Taxus brevifolia to elucidate the stereochemistry of the

38 ep of Taxol biosynthesis in the Pacific yew (Taxus brevifolia) is the cyclization of the linear isopr

39 urified taxadiene synthase from Pacific yew (Taxus brevifolia) stems to examine the possibility of a

40 rom poly(A)+ RNA extracted from Pacific yew (Taxus brevifolia) stems.

41 lex diterpene obtained from the Pacific yew, Taxus brevifolia, is arguably the most important new dru

42 on, a library was made from the stem bark of Taxus brevifolia.

43 grandis and taxadiene synthase (C(20)) from Taxus brevifolia], all of which are involved in natural

44 nt geranylgeranyl diphosphate synthases from Taxus canadensis and Abies grandis yielded a functional

45 A Taxus canadensis phenylalanine aminomutase (TcPAM) catal

46 The phenylalanine aminomutase from Taxus catalyzes the vicinal exchange of the amino group

47 cytochrome P450 oxygenases led to the use of Taxus cell cultures induced for Taxol production and the

48 mRNA isolated from methyl jasmonate-induced Taxus cells, from which several full-length acyltransfer

49 mRNA isolated from methyl jasmonate-induced Taxus cells, from which the full-length 10-deacetylbacca

50 cal to the recombinant enzyme and clone from Taxus chinensis, acquired recently by a reverse genetics

51 with the enzymes, depending upon the type of Taxus cultivars used.

52 ariety of taxane in extracts of a variety of Taxus cultivars were converted to a 10-deacetylbaccatin

53 ammonia lyase-like sequence acquired from a Taxus cuspidata cDNA library was expressed functionally

54 om sequencing of a cDNA library derived from Taxus cuspidata cells (induced for taxoid biosynthesis w

55 library constructed from mRNA isolated from Taxus cuspidata cells induced for Taxol production with

56 library (constructed from mRNA isolated from Taxus cuspidata cells induced with methyl jasmonate for

57 III:10beta-O-acetyltransferase isolated from Taxus cuspidata regiospecifically transfers short-chain

58 -O-benzoyltransferase has been isolated from Taxus cuspidata.

59 biosynthetic pathway, has been isolated from Taxus cuspidata.

60 xol) biosynthetic pathway and one additional Taxus-derived acyltransferases of unknown function were

61 s, Menlo Park, California) with those of the Taxus DES (Boston Scientific, Maple Grove, Minnesota) in

62 The CoStar DES is not noninferior to the Taxus DES based on per-patient clinical and per-vessel a

63 The Cypher and Taxus DES result in delayed arterial healing when compar

64 Cypher and Taxus DES showed greater delayed healing characterized b

65 Late stent thrombosis (LST) after Cypher and Taxus drug-eluting stent placement has emerged as a majo

66 (TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass S

67 diabetes, 3-vessel disease, or high SYNTAX (TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass S

68 Comparison Between DES Limus Carbostent and Taxus Drug-Eluting Stents in the Treatment of De Novo Co

69 e arterial reaction to overlapping Cypher or Taxus drug-eluting stents was examined in rabbits with b

70 (3:1), controlled, multicenter study of the TAXUS Element (vs. TAXUS Express) PES for the treatment

71 The TAXUS Element is a novel thin-strut (81 microm), platinu

72 At 1 year, the TAXUS Element is comparable in efficacy to the TAXUS Exp

73 of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System f

74 of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System)

75 and efficacy of the novel platinum chromium TAXUS Element paclitaxel-eluting stent (PES) compared wi

76 A prespecified analysis was conducted of the Taxus Element vs Xience Prime in a Diabetic Population (

77 The TAXUS Element was noninferior to TAXUS Express with resp

78 luded 1,262 patients (320 TAXUS Express, 942 TAXUS Element).

79 y artery bypass graft surgery [CABG]) versus TAXUS Express (Boston Scientific, Natick, Massachusetts)

80 nia) everolimus-eluting stent (EES) with the TAXUS Express (Boston Scientific, Natick, Massachusetts)

81 t is non-inferiority of TAXUS Liberte versus TAXUS Express for 9-month target vessel revascularizatio

82 was powered to demonstrate noninferiority to TAXUS Express for both end points.

83 ours of symptom onset were randomized 3:1 to TAXUS EXPRESS paclitaxel-eluting stents (PES) or EXPRESS

84 3-vessel disease to receive either PCI (with TAXUS Express paclitaxel-eluting stents) or CABG.

85 p is an entry-criteria-matched population of TAXUS Express patients from the TAXUS IV and V trials.

86 itaxel-eluting stent (PES) compared with the TAXUS Express PES (Boston Scientific, Natick, Massachuse

87 XUS Element is comparable in efficacy to the TAXUS Express PES.

88 fic Corp., Natick, Massachusetts) versus the TAXUS Express stent (Boston Scientific Corp.).

89 The TAXUS Element was noninferior to TAXUS Express with respect to both the incidence of targ

90 multicenter study of the TAXUS Element (vs. TAXUS Express) PES for the treatment of de novo coronary

91 -treat analysis included 1,262 patients (320 TAXUS Express, 942 TAXUS Element).

92 ficantly more complex for TAXUS Liberte than TAXUS Express.

93 rating that TAXUS Liberte is non-inferior to TAXUS Express.

94 were randomized (1:1) between a drug-eluting TAXUS Express2 and an uncoated Express2 control stent.

95 Patients receiving Taxus Express2 drug-eluting stents experienced a 1.28-fo

96 onfirmed increased risk following use of the Taxus Express2 stent but not the Angio-Seal STS device.

97 ow-up, IVUS lumen volumes were larger in the TAXUS group (123 +/- 43 mm(3) vs. 104 +/- 44 mm(3), p =

98 ears there were more stent thromboses in the Taxus group (hazard ratio 0.19 [95% confidence interval

99 hrombosis occurred in 1.28% +/- 0.31% in the Taxus group and 0.76% +/- 0.23% in the bare-metal stent

100 get-vessel revascularization was 9.1% in the TAXUS group and 19.4% in the control group (P=0.0027; re

101 s or IVUS parameters between the control and TAXUS groups.

102 Yew trees (Taxus) hyperbranch from long-lived buds that lie underne

103 ase using a single pAclitaXel elUting Stent [TAXUS]-I, -II, -IV, and -VI) (RR = 1.01, 95% CI 0.40 to

104 The relative benefit of Taxus is primarily attributable to reduction in TVR.

105 opulation of TAXUS Express patients from the TAXUS IV and V trials.

106 al restenosis rates from both the Pacitaxil (TAXUS IV) and Sirolimus (SIRIUS) drug eluting stents sug

107 TAXUS IV, V, and VI were double-blind, randomized, multi

108 erial intravascular ultrasound substudies of TAXUS IV, V, and VI.

109 Unique identifiers: TAXUS IV: NCT00292474; TAXUS V: NCT00301522; TAXUS VI: N

110 2.53, p = 0.99), trials with longer lesions (TAXUS-IV and -VI) (RR = 0.62, 95% CI 0.2 to 1.91, p = 0.

111 follow-up on revascularization rates in the TAXUS-IV trial and to determine whether the relative ben

112 The TAXUS-IV trial demonstrated that the slow-release, polym

113 The TAXUS-IV trial demonstrated the safety and effectiveness

114 In the TAXUS-IV trial, 1,314 patients were prospectively random

115 In the TAXUS-IV trial, 1,314 patients with single de novo coron

116 In the TAXUS-IV trial, 1,314 patients with stable or unstable i

117 In the TAXUS-IV trial, 1,314 percutaneous coronary intervention

118 In the TAXUS-IV trial, 1314 patients with single de novo corona

119 Using the angiographic substudy of the TAXUS-IV trial, in which 1,314 patients with de novo cor

120 In the TAXUS-IV trial, patients were randomized to the slow-rel

121 In the TAXUS-IV trial, treatment with PES led to substantial re

122 either PES (N = 662) or BMS (N = 652) in the TAXUS-IV trial.

123 nt in Patients with Coronary Artery Disease (TAXUS-IV) trial because of the high incidence of silent

124 th De Novo Coronary Artery Lesions (SIRIUS), TAXUS-IV, and the First and Second First Use to Undersco

125 rimary end point was met, demonstrating that TAXUS Liberte is non-inferior to TAXUS Express.

126 y (TL-PAS) contributed patients treated with TAXUS Liberte paclitaxel-eluting stent and prasugrel to

127 or 30 months reduced ischemic events for the TAXUS Liberte paclitaxel-eluting stent patient subset fr

128 al antiplatelet therapy with prasugrel after TAXUS Liberte paclitaxel-eluting stent remains unknown,

129 proven TAXUS technology to the more advanced TAXUS Liberte platform was demonstrated.

130 The TAXUS Liberte Post Approval Study (TL-PAS) contributed p

131 ssess non-inferiority of the next-generation TAXUS Liberte stent (Boston Scientific Corp., Natick, Ma

132 ntly lower in-stent LLL at 6 months than the Taxus Liberte stent did, with a trend toward better 12-m

133 patients enrolled, 162 received Cre8 and 161 Taxus Liberte stents.

134 esions were randomly assigned 1:1 to Cre8 or Taxus Liberte stents.

135 eristics were significantly more complex for TAXUS Liberte than TAXUS Express.

136 The primary end point is non-inferiority of TAXUS Liberte versus TAXUS Express for 9-month target ve

137 TAXUS Liberte was designed to combine the established po

138 permanent-polymer paclitaxel-eluting stents (Taxus Liberte, Boston Scientific, Natick, Massachusetts)

139 e the treatment of more complex lesions with TAXUS Liberte, the primary end point was met, demonstrat

140 ng clinical and angiographic outcomes of the TAXUS Moderate Release paclitaxel-eluting stent in the t

141 The finding that the TAXUS Moderate Release stent system is safe and effectiv

142 oss was 0.49 mm with CoStar and 0.18 mm with Taxus (p < 0.0001).

143 months was 11.0% for CoStar versus 6.9% for Taxus (p < 0.005), including adjudicated death (0.5% vs.

144 tents, there was a significant increase with Taxus (P=0.03).

145 om 32.9% in the control group to 9.1% in the TAXUS patients (P<0.0001).

146 were available in 170 patients, including 88 TAXUS patients and 82 controls, at implantation and at n

147 Approximately 0.8% of Taxus patients have stent thrombosis in the first 6 mont

148 The Taxus phenylalanine aminomutase (PAM) enzyme converts se

149 hylidene imidazolone (NH(2)-MIO) adduct of a Taxus phenylalanine aminomutase.

150 aclitaxel:N-benzoyltransferase (NDTBT), from Taxus plants, transfers a benzoyl group from the corresp

151 chanistically similar aminomutase TcPAM from Taxus plants.

152 nt-based meta-analysis using the 4 principal TAXUS randomized trials (3,445 patients) with a follow-u

153 from a stent coated with biostable polymer (Taxus) reduces restenosis after PCI.

154 No Taxus-related stent thrombosis occurred after 2 years (9

155 Of 8 patients with Taxus-related thrombosis after 6 months, 0 were taking c

156 was reduced among patients randomized to the TAXUS stent (2.6% vs. 6.3%, p = 0.02).

157 re similar in men and women treated with the TAXUS stent (8.6% vs. 7.6%, respectively, p = 0.80), as

158 restenosis in women was randomization to the TAXUS stent (OR = 0.28 [95% CI 0.11 to 0.74], p = 0.01).

159 sel revascularization rate was 7.9% with the TAXUS stent and 18.6% with the bare-metal stent (p = 0.0

160 between the two groups, and reduced with the TAXUS stent at the distal edge (p = 0.004).

161 w-release, polymer-based, paclitaxel-eluting TAXUS stent compared to bare-metal stents in patients un

162 By actuarial analysis, the TAXUS stent compared with the bare-metal stent reduced t

163 hs for the polymer-based, paclitaxel-eluting TAXUS stent compared with the EXPRESS stent is preserved

164 ients per 6 months) were similar between the Taxus stent group (0.59 [95% confidence interval 0.22 to

165 t surgery due to restenosis is reduced after TAXUS stent implantation in LAD lesions.

166 mpared to control stents, treatment with the TAXUS stent in women resulted in a significant reduction

167 w-release, polymer-based, paclitaxel-eluting TAXUS stent or a bare-metal EXPRESS stent (Boston Scient

168 w-release, polymer-based, paclitaxel-eluting TAXUS stent or a bare-metal EXPRESS stent (Boston Scient

169 w-release, polymer-based, paclitaxel-eluting TAXUS stent or an identical bare-metal stent; 536 (41%)

170 w-release, polymer-based, paclitaxel-eluting TAXUS stent or an identical-appearing bare-metal EXPRESS

171 ate-release polymer-based paclitaxel-eluting TAXUS stent or the bare-metal EXPRESS stent (Boston Scie

172 randomized to either the paclitaxel-eluting TAXUS stent or to its bare-metal equivalent, we defined

173 In the insulin-requiring subgroup, the TAXUS stent reduced angiographic restenosis by 82% (7.7%

174 n 2.5- to 3.75-mm vessels were randomized to TAXUS stent versus bare-metal EXPRESS stents (Boston Sci

175 The use of the paclitaxel-eluting TAXUS stent was safe in patients with unstable ischemic

176 s (including 187 women) were assigned to the TAXUS stent, and 652 (180 women) received the control st

177 Among patients with diabetes, the TAXUS stent, compared to the bare-metal stent, reduced t

178 Among patients receiving the TAXUS stent, women compared with men had higher unadjust

179 stent thrombosis with the paclitaxel-eluting Taxus stent.

180 observed in only 3.0% of control and 4.0% of TAXUS stents (p = 0.12).

181 Polymer-based, paclitaxel-eluting TAXUS stents are effective in inhibiting neointimal tiss

182 r, a modest increase in risk is present with Taxus stents beyond 6 months, possibly because of inadeq

183 Taxus stents induced greater fibrin deposition, medial c

184 Overlapped segments in Taxus stents induced significantly more luminal heteroph

185 The successful transfer of the proven TAXUS technology to the more advanced TAXUS Liberte plat

186 stablished polymer-based, paclitaxel-elution TAXUS technology with the more advanced Liberte stent pl

187 e cardiac events (MACE) occurred in 13.5% of TAXUS-treated patients versus 21.2% treated with the con

188 Unique identifiers: TAXUS IV: NCT00292474; TAXUS V: NCT00301522; TAXUS VI: NCT00297804.

189 TAXUS VI is a prospective, multicenter, double-blind, ra

190 TAXUS IV: NCT00292474; TAXUS V: NCT00301522; TAXUS VI: NCT00297804.

191 differential display-cloning approach, using Taxus (yew) cells induced for Taxol production, yielded